Nutriband, Kindeva select Aversa Fentanyl for commercial scale manufacturing

Nutriband with Kindeva Drug Delivery have selected the target AVERSA formulation to take forward into commercial scale manufacturing process development for the Company’s patented lead product, AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA Fentanyl contains Nutriband’s proprietary transdermal abuse deterrent technology which can be manufactured using standard commercial transdermal manufacturing processes and is currently available for incorporation into a variety of transdermal patch products. AVERSA Fentanyl combines Nutriband’s proprietary AVERSA abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system